Issue 44 - Nov. 20, 2020
TCL46-44 (356 downloads)

  • Conversation with The Cancer Letter

    ASCO’s new CMO Julie R. Gralow will focus on equity, advocacy, and global health

    Julie R. Gralow, an expert in breast cancer, clinical trials and global health, was named chief medical officer of the American Society of Clinical Oncology.

  • Cancer hospitals stay open as COVID-19 cases skyrocket

    The United States faces the worst-yet surge of COVID-19, but cancer hospitals have learned to adapt to the pandemic, opting to continue cancer services at an unchanged pace.

  • News Analysis

    Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot

    On Nov. 15, shortly after midnight, President Donald J. Trump tweeted a link to a New York Post headline:

    “Tax filings reveal Biden cancer charity spent millions on salaries, zero on research”

    Waking up later that morning, Fox News host Laura Ingraham and former Trump campaign manager Corey Lewandowski, gleefully lent their voices to the now-familiar cacophony of disinformation. A day later, Fox News host Sean Hannity joined their chorus.

  • Letter to the Editor

    AACI: President-elect Biden has proven his unyielding commitment to defeating cancer

    In a year of monumental health care and operational challenges for cancer centers, the Association of American Cancer Institutes marks with enthusiasm the electoral victory of a presidential candidate who has proven his unyielding commitment to defeating cancer.

  • In Brief

    • Hannah Hazard-Jenkins named director of WVU Cancer Institute
    • Edward S. Kim named physician-in-chief of City of Hope Orange County
    • Julia H. Rowland and Tom Smith receive NCCS Ellen L. Stovall Award
    • Jedd Wolchok receives Hearst Foundation Grant
    • CPRIT awards $26 million in new recruitment grants
    • New AMA policy recognizes racism as a public health threat
    • ASTRO: Radiation oncologists urge Congress to advance bills that protect patient access to cancer care during the pandemic

  • TCCL Logo

  • Clinical Roundup

    • In vitro fertilization does not increase the risk of ovarian cancer
    • UCLA researchers find patients with lung cancer most likely to respond to immunotherapy
    • AI can pick the best candidates for skin cancer treatment
    • Phase III trial shows decrease of chemotherapy-induced neutropenia
    • Neratinib in HER2-positive HR-negative early stage breast cancer shows DFS benefit vs. placebo

  • Drugs & Targets

    • Keytruda receives accelerated approval from FDA for locally recurrent, unresectable or metastatic TNBC
    • FDA issues draft guidance to provide important considerations in cross labeling of oncology drugs
    • CDER and CBER to increase Emergency Use Authorization transparency
    • Agendia and Paige collaborate on breast cancer research
Issue 43 - Nov. 13, 2020
TCL46-43 (185 downloads)

  • News Analysis

    Joe Biden has an unparalleled grasp of the science and politics of cancer

    For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research.

  • Guest Editorial

    A Biden-Harris administration will help sustain our momentum in the fight against cancer

    The recent historic election of President-elect Joe Biden and Vice President-elect Kamala Harris provides an exciting opportunity for the cancer research and medical science communities during the next four years to dramatically improve the health of our nation and the world.

  • An Appreciation

    David A. Ahlquist, pioneer of cancer screening, dies at 69

    With unwavering positivity and unquenchable curiosity, David A. Ahlquist, MD, turned complex challenges into addressable opportunities, and audacious ideas into achievable realities.

  • In Brief

    • Abraham Chachoua named director of Perlmutter Cancer Center’s Lung Cancer Center
    • CWRU and UH Researchers receive $5 million from NCI to investigate relationships between HIV and lung cancer in East Africa
    • John Turchi receives $2.9 million from NCI to improve effectiveness of lung cancer radiation therapy
    • SWOG and The Hope Foundation award two grants designed to give military veterans better access to cancer clinical trials
    • The US Oncology Network enrolls 100,000th patient in the Oncology Care Model

  • TCCL Logo

  • Trials & Tribulations

    #BCSM: Breast cancer social media hashtag gives voice to a community

    When they decided to launch a weekly breast cancer chat on Twitter, all breast cancer survivors and advocates Alicia Staley and Jody Schoger had was a hashtag and a dream.

  • Clinical Roundup

    • Keytruda + Lenvima meet PFS primary endpoint in advanced RCC
    • KEYNOTE-695 study: Tavo + Keytruda demonstrate 30% ORR in anti-PD-1 checkpoint refractory metastatic melanoma
    • State-level lung cancer screening rates are not aligned with lung cancer burden in the U.S.
    • Diagnostic imaging may increase risk of testicular cancer
    • JNCCN study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
    • Research detects hormone-upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase discovered in prostate cancer

  • Drugs & Targets

    • FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
    • FDA issues guidance to enhance diversity in clinical trials, encourage inclusivity in medical product development
    • European Commission approves Opdivo + Yervoy with two cycles of chemotherapy for first-line treatment of metastatic NSCLC
Issue 42 - Nov. 6, 2020
TCL46-42 (557 downloads)